LISA O'DONNAL: Open Payments
NPI 1124584867 · RICHFIELD, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,554 in 74 payments from 14 companies in 2025. Trend: 2023 $935 · 2024 $1,765 · 2025 $1,554
Food & beverage: $1,550Education: $4
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $253 |
| Teva Pharmaceuticals USA, Inc. | 17 | $238 |
| Alkermes, Inc. | 10 | $206 |
| Neurocrine BioSciences, Inc. | 10 | $196 |
| Otsuka America Pharmaceutical, Inc. | 4 | $180 |
| Braeburn Inc. | 3 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $90 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| Vanda Pharmaceuticals Inc. | 3 | $83 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
Products named: VRAYLAR, AUSTEDO XR, INGREZZA, REXULTI, ARISTADA, BRIXADI, LYBALVI, CAPLYTA.
Industry payments across UT — which companies pay providers there.
